by
Lisa Chamoff, Contributing Reporter | October 18, 2021
From the October 2021 issue of HealthCare Business News magazine
“We’re happy to be viewed by the federal government as new, which could have other benefits down the road,” Mazin said.
Stanford and the City of Hope cancer center in California already use the X1 for image-guided radiotherapy using CT.
Ad Statistics
Times Displayed: 19090
Times Visited: 362 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
“We hope that BgRT will one day provide metastatic disease patients with more treatment options than they have today. Studies in patients with limited metastatic disease are showing that just adding conventional radiotherapy provides not just months of benefit, but one to two years of benefit for Stage 4 cancers,” Mazin said.
Also last year, RefleXion announced a clinical collaboration to evaluate BgRT with Merck's KEYTRUDA for certain late-stage cancers.
“We believe that this is a sign that combination therapy is the next frontier,” Mazin said.
Pyrexar
Pyrexar is awaiting installation of its BSD-2000 3D/MR, an MR-guided hyperthermia system, in Turkey and Taiwan.
The system, used in conjunction with radiotherapy for recurrent cancers, delivers RF energy waves to the tumor, with MR imaging providing information on heat volume.
The base unit (BSD-2000) without MR guidance is currently FDA cleared for cervical cancer with a humanitarian device exemption, said Mark Falkowski, chief executive officer at Pyrexar.
TeamBest Companies
In 2021, Best Cyclotron Systems, a member of Team Best Global, released a number of new cyclotrons, including a B35adp alpha/deuteron/proton cyclotron; a B3d low energy proton/deuteron cyclotron; a 100 MeV variable energy cyclotron proton therapy system; a 15 to 35 MeV variable energy, high-current proton cyclotron; and a 6–15 MeV compact, high-current, variable-energy proton cyclotron.
Best Cyclotron Systems also announced an upgrade of its Best 35–70 MeV proton cyclotron to 1000 µA, while Best ABT, a TeamBest Global company, introduced the Best Sub-Compact Model 200 self-shielded cyclotron for radioisotopes.
TeamBest Global Companies also won an international tender for a 6 MeV high-current proton cyclotron, which the company says is the first cyclotron of its kind in the world.
Krishnan Suthanthiran, president of TeamBest, said the company is willing to partner with cancer centers to help them operate and service their cyclotrons.
"These technologies are highly complex and need to be expertly operated," Suthanthiran said.
Xoft
Xoft, a subsidiary of iCAD Inc., is expanding use of its electronic brachytherapy device into new therapeutic areas. It’s currently used for the treatment of early-stage breast cancer, nonmelanoma skin cancers and gynecological cancers, although it is FDA cleared, CE marked and licensed in a growing number of countries for the treatment of cancer anywhere in the body. The company recently developed a new applicator for rectal cancer and there is currently a trial underway to evaluate the use of Xoft for the treatment of rectal tumors.
